Tenax Therapeutics Inc logo

Tenax Therapeutics Inc

$ 0.18 -0.0131 (-6.93%) 10:08 PM EST
P/E:
At Loss
P/B:
0.64
Market Cap:
$ 4.43M
Enterprise V:
$ -2.13M
Volume:
306.34K
Avg Vol (2M):
514.78K
Also Trade In:
Volume:
306.34K
Market Cap $:
4.43M
PE Ratio:
At Loss
Avg Vol (2-Month):
514.78K
Enterprise Value $:
-2.13M
PB Ratio:
0.64
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Name Current Vs Industry Vs History
Cash-To-Debt 21.84
Equity-to-Asset 0.81
Debt-to-Equity 0.05
Debt-to-EBITDA -0.03
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -4.25
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 26.98
9-Day RSI 33.51
14-Day RSI 35.28
6-1 Month Momentum % -64.44
12-1 Month Momentum % -81.56

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.6
Quick Ratio 5.6
Cash Ratio 5

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -88

Financials (Next Earnings Date:2022-11-15 Est.)

TENX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:TENX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.41
Beta 2.37
Volatility % 77.93
14-Day RSI 35.28
14-Day ATR ($) 0.03926
20-Day SMA ($) 0.21019
12-1 Month Momentum % -81.56
52-Week Range ($) 0.16 - 1.9594
Shares Outstanding (Mil) 25.21

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Tenax Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Tenax Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.